NASDAQ:ATNX

Athenex Stock Forecast, Price & News

$3.99
+0.04 (+1.01 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.80
Now: $3.99
$4.00
50-Day Range
$3.95
MA: $4.51
$5.46
52-Week Range
$3.76
Now: $3.99
$15.24
Volume1.21 million shs
Average Volume2.79 million shs
Market Capitalization$372.89 million
P/E RatioN/A
Dividend YieldN/A
Beta0.92
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Athenex logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATNX
CUSIPN/A
Phone716-427-2950
Employees593
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$101.23 million
Book Value$2.15 per share

Profitability

Net Income$-123,750,000.00

Miscellaneous

Market Cap$372.89 million
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

Headlines

Athenex, Inc. (NASDAQ:ATNX) Short Interest Update
April 15, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.63 out of 5 stars

Medical Sector

371st out of 2,018 stocks

Pharmaceutical Preparations Industry

173rd out of 772 stocks

Analyst Opinion: 4.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$3.99
+0.04 (+1.01 %)
(As of 04/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Athenex (NASDAQ:ATNX) Frequently Asked Questions

Is Athenex a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Athenex in the last year. There are currently 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Athenex stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATNX, but not buy additional shares or sell existing shares.
View analyst ratings for Athenex
or view top-rated stocks.

What stocks does MarketBeat like better than Athenex?

Wall Street analysts have given Athenex a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Athenex wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Athenex?

Athenex saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 13,240,000 shares, an increase of 110.2% from the March 15th total of 6,300,000 shares. Based on an average trading volume of 2,970,000 shares, the short-interest ratio is currently 4.5 days. Currently, 17.5% of the company's stock are short sold.
View Athenex's Short Interest
.

When is Athenex's next earnings date?

Athenex is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Athenex
.

How were Athenex's earnings last quarter?

Athenex, Inc. (NASDAQ:ATNX) announced its earnings results on Sunday, February, 28th. The company reported ($0.53) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.09. Athenex had a negative net margin of 75.45% and a negative trailing twelve-month return on equity of 66.12%.
View Athenex's earnings history
.

How has Athenex's stock been impacted by COVID-19?

Athenex's stock was trading at $9.66 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ATNX stock has decreased by 58.7% and is now trading at $3.99.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ATNX?

9 analysts have issued 12-month price objectives for Athenex's shares. Their forecasts range from $5.00 to $33.00. On average, they anticipate Athenex's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 275.9% from the stock's current price.
View analysts' price targets for Athenex
or view top-rated stocks among Wall Street analysts.

Who are Athenex's key executives?

Athenex's management team includes the following people:
  • Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D., Chairman & CEO (Age 61, Pay $880.75k)
  • Mr. Randoll Sze, Chief Financial Officer (Age 40, Pay $375.21k)
  • Mr. Jeffrey M. Yordon, COO & Pres of Athenex Pharmaceutical Division (Age 72, Pay $584.76k)
  • Dr. Rudolf Kwan M.D., M.B., B.S., Chief Medical Officer (Age 68, Pay $510.17k)
  • Dr. Simon C. Pedder Ph.D., Chief Bus. & Strategy Officer of Proprietary Products (Age 60, Pay $378.71k)
  • Dr. Allen Barnett, Co-Founder & Pres Emeritus
  • Ms. Teresa Brophy Bair, Gen. Counsel, Sr. VP of Admin. & Corp. Sec.
  • Mr. Steven Rubis, Sr. Director of Investor Relations
  • Ms. Jacqueline Li, Director of Corp. Devel. & Investor Relations
  • Mr. Daniel Lang M.D., Sr. Director of Corp. Devel.

Who are some of Athenex's key competitors?

What other stocks do shareholders of Athenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athenex investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), QUALCOMM (QCOM), Amarin (AMRN), AbbVie (ABBV), Gilead Sciences (gild), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

When did Athenex IPO?

(ATNX) raised $72 million in an initial public offering on Wednesday, June 14th 2017. The company issued 6,000,000 shares at $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan acted as the underwriters for the IPO and ICBC International was co-manager.

What is Athenex's stock symbol?

Athenex trades on the NASDAQ under the ticker symbol "ATNX."

Who are Athenex's major shareholders?

Athenex's stock is owned by a variety of institutional and retail investors. Top institutional investors include Deltec Asset Management LLC (0.70%), First Midwest Bank Trust Division (0.44%), Defender Capital LLC. (0.02%) and Pacer Advisors Inc. (0.02%). Company insiders that own Athenex stock include Benson Kwan Hung Tsang, Johnson Yiu Nam Lau, Jordan Kanfer, Kim Campbell, Life Sciences Maste Perceptive, Manson Fok, Perceptive Advisors Llc, Randoll Sze, Rudolf Kwan, Stephanie A Davis and William Wei Zuo.
View institutional ownership trends for Athenex
.

Which major investors are selling Athenex stock?

ATNX stock was sold by a variety of institutional investors in the last quarter, including Deltec Asset Management LLC.
View insider buying and selling activity for Athenex
or view top insider-selling stocks.

Which major investors are buying Athenex stock?

ATNX stock was bought by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, Defender Capital LLC., and Pacer Advisors Inc.. Company insiders that have bought Athenex stock in the last two years include Benson Kwan Hung Tsang, Johnson Yiu Nam Lau, Jordan Kanfer, Kim Campbell, Life Sciences Maste Perceptive, Manson Fok, Perceptive Advisors Llc, Randoll Sze, Rudolf Kwan, and Stephanie A Davis.
View insider buying and selling activity for Athenex
or or view top insider-buying stocks.

How do I buy shares of Athenex?

Shares of ATNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athenex's stock price today?

One share of ATNX stock can currently be purchased for approximately $3.99.

How much money does Athenex make?

Athenex has a market capitalization of $372.89 million and generates $101.23 million in revenue each year. The company earns $-123,750,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis.

How many employees does Athenex have?

Athenex employs 593 workers across the globe.

What is Athenex's official website?

The official website for Athenex is www.athenex.com.

Where are Athenex's headquarters?

Athenex is headquartered at 1001 Main Street Suite 600, Buffalo NY, 14203.

How can I contact Athenex?

Athenex's mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The company can be reached via phone at 716-427-2950.


This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.